-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FamHhgSaG0TSjTyhN3qQdiuuRDfwWS4AE238fRYOLM/Wk546Nlht2LUzkdejIoSO b04CeJJyTzSuB/pIja/Vvg== 0000950103-05-000284.txt : 20050215 0000950103-05-000284.hdr.sgml : 20050215 20050215133514 ACCESSION NUMBER: 0000950103-05-000284 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20050215 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050215 DATE AS OF CHANGE: 20050215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 05616169 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 feb1505_8k.htm feb0305_8-K
   
   
UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
 
Washington, D.C. 20549 
   
   
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 

Date of Report (Date of earliest event reported):     February 15, 2005

Shire Pharmaceuticals Group plc

(Exact name of registrant as specified in its charter)
 
England and Wales

(State or other jurisdiction of incorporation)

0-29630   98-0359573
(Commission File Number)   (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England

(Address of principal executive offices)                                                (Zip code)

Registrant’s telephone number, including area code                    44 1256 894 000

 

(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 8.01. Other Events

      Shire Pharmaceuticals Group plc has issued the press release attached as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

               (c)  Exhibits. The following exhibit is filed herewith:

99.01            Press Release dated February 15, 2005





 

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  SHIRE PHARMACEUTICALS GROUP PLC
     
  By:   /s/ A C Russell
 
  Name:  Angus Russell
  Title:    Chief Financial Officer

Dated: February 15, 2005

 






EXHIBIT INDEX

Number Description
   
99.01 Press Release dated February 15, 2005




EX-99.1 2 item9901.htm exhibit 9901
Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000  Fax +44 1256 894708

http://www.shire.com
 
Exhibit 99.01
 
 
 
 
 
     
     
15 February 2005    

Shire Pharmaceuticals Group plc (the "Company")

The Company announces that on 11 November 2004, Dr James Cavanaugh, the Chairman and a non executive director of the Company , acquired 296,571 ordinary shares of £0.05 each in the Company through a distribution from a partnership fund.

As a result of this transaction, Dr Cavanaugh has a total interest in 412,849 ordinary shares of £0.05 in the Company. The Company was notified of Dr Cavanaugh's interest in these shares on 11 November 2004.

T May
Company Secretary

For further information please contact:

Investor Relations    
     
Cléa Rosenfeld   +44 1256 894 160

Notes to editors

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com.


GRAPHIC 3 logo.gif GRAPHIC begin 644 logo.gif M1TE&.#EA2@&=`/<```P(:"E(:+ MFX:+HX:+JH:+P(:5L8:5N8:>L8:>N8:GP)"5P)"5R)">N9">P)"GP)"GR)"P MUIN>HYN>JIN>N9N>P)NGL9NGN9NGR)NPR)NPSZ6>JJ6>L:6>R*6GN:6GP*6G MR*6GWJ6PR*6PSZ6PUJ6PWJ6ZWJ6Z[*7#WK"PL;"PN;"PP+"PWK"ZR+"ZS["Z MUK"ZWK"Z[+##S[##UK##WK##[+#,Y;JZP+JZR+JZS[JZUKJZWKK#WKK#[+K, MY;K,[+K5[,7#R,7#S\7#UL7#WL7#],7,R,7,S\7,UL7,Y<7,[,75Y<75[,7? M^\_,R,_,S\_,UL_,WL_,[,_5S\_5UL_5WL_5[,_?],_H^]K5UMK5WMK5Y=K5 M[-K?WMK?Y=K?]-KH^^3?[.3HWN3HY>3H[.3Q^^_H]._Q]._Z^_KQ]/KQ^_KZ M[/KZ^P`````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````/___R'Y!`$``/\`+`````!*`9T`0`C_`/\)'$BPH,&# M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/`WF5ZC40F"R+3RH(`8E0UDF6 M,&/*G$FS)D)>+WNITL@HIBQ>`H?MDA7+IM&C2),J16@K%5"84"1H<#&0AP.J M$G_)2O7RWRU9O7`N'4NVK-FS!*-FB&(*%Q0M((?)NG5+X*RZ://JW7?2-+GJQQ&*FNJ68!\S778@7!=QR\D53AAT:7 M3__AW)6:LNO7L!F:/&FRM<1A6"0XB.)"0AN!9RX48&5QZ,]A`F_-BLV\^6M@ MHP3R`FH9(PL)DUAA(#%(0HN!GC*\_YC(:Y=`R,[3J^_;ZU8O6<@3`ILX0H*3 M$R=8A3:SOK___PO]A%$@!0PAD!NZH2%0,``VZ&!SMO`2WWS_R"4+A1$-0\8( M&>RP2B$92$#"$"-44,J#**;8EWL#O:?BBS#&*%TJ!+F$7"RV230+*0!"`L," M`0@@```&&%!``44VP("00PY@P`R&)%0&!@59%<&5$4``@0,I=$1&%PYH*29@ M(S`H(UIR"=0>+['$1Q$I.?Q`4F2>.%!``!NX\@\B0!H`P`$4+`2"D`,,```` M!!!90!X*Q1#``$Q""H`#9U8*T87K%1)!`0LHJ)"F`1Q@*`&%EEHJ`(8>>FB1 M`2P00R0.P?_PJ*%"JFI`JT>HH<81'00`@`"0,BE``!TH!$41J!8*[*$%")-0 M!\*:FNJA`2`)P)U=%#1%`;\FFV@!:QC$IP'*JEH`(982Y.9>"]Q:P$.KT.## MO/3.2\,;#.%RIP%#'BKJM50D)&NPRTZ:D"1!2BM``68>=&RRD*;:[+,0GTJ$ M0WJ$>JBP!U#KJZH`!""RR$4:>6<`.Z4+T2Q@#639G!V=<*B3>DK$10#D*@OL MM/WZBZJHD1IJ9+:-/BKLH90BA/#.I2[`4_<*8RRR7(B#MR$=F M(4F+0_1#!8[DDD$%JRS8R"87L5G2[?^89%[RX)LUVUTY/K1)';X@M`J'$A@X MT?$XP1?^_$O%,J=)19U(T@=X%(*7Z`@0I`P4S!(&%ITL?!%K[&3:7[ MX#]L44"*L*`%;I&`&7)1@?%<9!@:=*$0_V-BNX$$3D+HF0@+"O`'!@W!`=@; MHA1=$Z$*\6(^M\B?0YA0@3I,\8NOV<4OAF$+[E6H;6GPE0!8M0`:(&(.'BB9 MGYHTJFDQ"PH&641!!J:S825M(T1`EJ%.9:2G@1$MO%"%#+$UA[D0(/"/&K%D:!%H[PQHD&2)- M8#'I4(%*B">HP(4J^+0*5)C"(PPXG?]])!=H($(*3&`"'@SA#5%TB##`\`"2 MA4R.(Q/9D4Y0B(@$H@MF\((7NN`%-*#!BPBY11?0D(:VFM4,U3S((R!AUC"` MP:QCI6!"\$!6L[K5#$.UB"O6T`$@955DKMHD-&T!#*-"\[&0-2!J!&*2BNPB M%JRAB5P".)`D1O:+-!QC]P:R"V"L[2S?(^UD/_M9L4C'@[*+""!HPHO+(`/3F7^0PK$.(4,%Q@`3G/_`KGLTTNUCX]<5E]AH+W*)1>(L*(L:*A>T MJ;$M1F(KD#9(0#<2&`$N)`*,`F+JNNCE"!8J4``@.,$!&7#$/WJ@3<]5Y"4M MFV%Z#QF+Z,BD#2$B06(N8EJ%&'>_"&8((##`J($8P@45P$`+`J$1D]PE9=*1 M1>@2S&&$U,E].BB`=SQBDMQVN(6740@P/#B1$)R0!!)@A2`L,%^5A$%7-YBHZI?$!@I"*U(+&#!"@@`4_\8P<2.$'U,M3?UOQ"NCPF,^UN M3$:!I,+_Q`V9Q0]F*Q!5Z4C7JQZ(>NEID#@(($' M#.$!>)3WB7<1'UZ$9;KR>\A?!/&/,[1O((84^(D]>Q%:.&`':7#`$((1A1!D MA!?)E?@&Y8>I-%6D$5A`G\A7KAI22T05[V;YQ"ETEV#+_.8&__%O915X$1M4 M@$C!0F!@2D*1U$MF MD,`$1C^![X9W[557"/[,@@L'+*``/!!(+E:`,TNFR@`U0\@CA,"#'O3`Z$,@ MPA"$0&B$B-1K`(BH0+KP^EL1:60%F()#M+`%3BW@^J\OP`;&BY`71-WZ!<## M0/A@V%L%(*X(@8,'M`HV:A4``E!@I>_*[OV:2'"`\=POB".]9E-:"``"*4J"T"`U;8'`:``X`(2PA`'(#""JA*!BE()(14DWW0HRG<0B""'<\AW M4"-(\22!3R@M3B(##A$'CU(QA?(G37(`$6AY@!@`K1`^M?45:/_F$?H2)(+X M$/HB*O$D-&'8$!`P)/URB`50!0)C-)YG,$J3,$WC-._$ARQU+54X$+6D,X8R M4PHA#`NP3,(2`!AU2.4%%D*&%\/`,A^A`LO$`1*1"Q+@*Q5U4X;2*A"@`C$P MC1/P>G_24`4 M`X]($)[02_PB*<,"`R[4:!O1"KV",P6@`H:`CO_P"YJ0"?XU$,SG2SU3+M]T M*AUU+0M@!0TQ,-XT+'5H$%QS@XKB@X'T=3>5?&)8$!U@@Y(23.X3$7GP`$CB M2[;4AJD"*>ZB>8]&;*EWDPPA>#BYDSO_.12IY1)?P5T-T6?2$0N4YA&H,6IY MQI,-HA7O@1=".92G)A,B(4-J,F1,^2([5R$4MQ>7-3Q`A"/.E965\@LY,@PX M07\+D0E&T5AD62GO(3<&AVHH40$LL)09,8P>9`LL^)8J,I=!9I624491Z91L$,0H7-(FOZ2"I&9@'=Q%8$`)^ MD!!U(`&EX8,&=CN=4Y"ZN9L`4@L20EDP$7H2(`*.4`0.T`)S!A$6Q)6I\16: MZ9R,(P0.\%TN_S!GK*`;&&81BBD=@R>>?E,B6"`07%">,"8!6[!=E,59?0F? M`&*6-%$'I7$1XB9=!N:?X<,%ID=W+``3E_$56X>@?4,&Y?D;!?&>$+%B(=19 ME"FAKK$+Q,`23/!=;>`)66!"&&%!J8$IP/`5M>FA>E$,+$$(!1`%G_`"(V`( M(N``*7@:CPFCLP,%#F`&A&`*64`"X\4%.T`&$9HA"]0]T0FDZP%I&L$)@L`) MHZ5F9W`*)!`"/6J;7'D\3RJE#:*AYO80OA`"%?`/;5`!!O(##9:B>!$_J0%$ M(4>FSA$_&"*8#.$+)80##O`[W=,"1R($+$01HR8@,AID8(:GZO&4[^W1%4)F M$6/`(QF@>8Y0`?FI$9'HJ`ZBEQB:$"R``<3A`@X0"9Z`E1;!"_'V7%H1JI[: M%WI9$8X`80`(7(`$!)PC?-0+,VA`TM!JJ%9XP M:Q1`5%V-,6G^>A"!P`*'40:K4#T*>K(;,98;>[1],3P"T@LN-Q%F4`&^(1"E M<#T8L0N>,VE#H;61@1[[BA&EX`"=\`^0`%\9\`K!X`(%\&GOLQ5LZQIH&6RR M0`I!JV+)]@^X$&&9YBE_^S8+>Q[AF0LCX`!"$`BXT`(*`@Q/D`-DT+@J@YCO MX2:A2Q&FL`/B@2YO)J@7`0O7ZKEG(3SJ\A,N`:L%T0(6P*Z<8+K?A;JN:RG\ M:!&-H`,L4!\2P*[!(`08$`+SV;LP8D$4@I;2-J8/,0LCL`1N:0@%_X`"#8TP:`#%R<"$A![ MF%9".O!M[OL@;-(5P`!FM)L0DZL`4?`/>6L:&$&4_YL7;)(:P+`81DL0M."F M_Y`+/#`]#/S`,$(W,@28$E$*-U`!(:`#J_!`'APC(8<3&[K"],,RU!8?9(2P M,$P_`YQ?,]2?#V$+:MK!-YPB(NQ!I8"Q!E&X0>P@BLDR$R(+QE/`2:PR7$L2 MY3L1C*"F?1#%*6*3"O2P#C&,;K,*>=`%0Q`#2V4"+\`#;["=P6H[0124912M M;D,(5)`"=O)]6G4D1?(%B?`*8H@+A3`$$O_K=N,J%V%!(:/`PP_A!R'``DV+ M%D1@50BX*C6@!`V@BR`57("(3\#XXT,TP2`*)L$3UEB,&T M`/+*6F3DQ1CAPGD1#!OE,3,0"O\0R2>357^2`#EXC892`$3X#WI$$`/CAL=< M$4T0R38H)$5"CJ4)E*K1RDO1!G:R`$7P"J]0!=WX M>5J<%]QV)`\0!_L&)&2#C`K1!2+C,0`9`#%G$,>G+*U"$,)`"$D5`SU`!&CP M"%!L$,:0$920!VK_@`9X`,W_T`J$L`5$T`,Q0`-3@`:0T,PI8ADP#1MF8"<1 M@+J/L`')(CAM!!3D`38""R)PLP3F"JI!`!BX$B**"F*@GX" M`0E5A=@;,T(B%HH@A[`1H*`'18`"J0V3CST`'6,DW`B*J9*1!;$T M(V7BK7@U]ZWB&YY3#%$(!1"341@VAU4MOF2(L`@W"900$3P3K>``?H+>'A$* M7N"%HEW6UZ(&<3A2AN+D!'&'T1+.)VZ.5?Y2*V8.`#[@$&OPCMTX2#9UA/VB MZ,-"T*/3J:O'$EP`@+W8$%K>?EO]X`L!"@O`Y#EH3Z5XT*AX$.'8-/`\$"@^ MYG^XB>S8$)Y@+3AH`$9@!6+E!5;P!;7N!55@Z[7>!;[>!2D].WKYP@K_],@1 MP70ATU40T2YT='L!X-`+\0HFZ5%GB!#G?(KI7.K!I.:.6TV.H-00') M1>M(+,00*```(X`$2D3$&@``Z6"M&@@1,+0Q4T"[8*([7 MLN38?C"JJ-_<7M]^GN(O]4TR!2\)<]34?8D&D>8G8];5$M@;%`ONCA`;8`"D M@N40<>GE'I+!%#;F5]X!_Y*W,F#I+>K9?O`;D_#>3I#J2#9LKA`3X"=(?HT' M<"0;<'1$4%4!@.^&@N_7HNP;Q#*DD`K`H,@3@09!0MTYSQ`]L$YM>'D8^"^= MQR14SQ"#+23&G!"18.@(W^<@.3;?#NCY+>X/CT'18(/O`I!*J83;M7+>CS9E M("$'A15U@?$".I`#.1`$3T`';*D^45#D(`.*/6.#K!(`'H`&!%D0)_`Q%7TG MZ0P)7^YTIAU\7^XNIKT!3>
-----END PRIVACY-ENHANCED MESSAGE-----